U.S. Markets closed

Gossamer Bio, Inc. (GOSS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.02+0.77 (+9.33%)
At close: 04:00PM EST
9.47 +0.45 (+4.99%)
After hours: 06:58PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.25
Bid8.57 x 2200
Ask11.00 x 1400
Day's Range8.12 - 9.05
52 Week Range5.64 - 15.19
Avg. Volume1,441,100
Market Cap689.701M
Beta (5Y Monthly)0.95
PE Ratio (TTM)N/A
EPS (TTM)-3.55
Earnings DateMar 01, 2023 - Mar 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.15
  • Benzinga

    Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial

    Raymond James maintains Outperform on Gossamer Bio Inc (NASDAQ: GOSS) with a price target down from $18 to $15. The analyst expects a somewhat smaller effect size for seralutinib vs. sotatercept's. Seralutinib Phase 2 TORREY study is on track for topline readout in the second half of November or the first half of December. Merck & Co Inc (NYSE: MRK) is developing sotatercept as an add-on to stable background therapy for pulmonary arterial hypertension (PAH). Merck recently reported topline data

  • Zacks

    What Makes Gossamer Bio (GOSS) a New Buy Stock

    Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  • Business Wire

    Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update

    SAN DIEGO, November 03, 2022--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the third quarter ended September 30, 2022 and provided a business update.